Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma
Nira A. Krasnow(University of California, San Francisco), Caron A. Jacobson(Dana-Farber Cancer Institute), Liliana Guerrero(Dana-Farber Cancer Institute), Brodie Miles(Children's Cancer Therapy Development Institute), Robert Redd(Harvard University), Mike Mattie, Timothy Blewett(Broad Institute), Caitlyn Duffy(Harvard University), Justin A. Budka(Gilead Sciences (United Kingdom)), Catherine J. Wu(Dana-Farber Cancer Institute), Katie Maurer(Broad Institute), Philippe Armand(Harvard University), Heather A. Jacene(Brigham and Women's Hospital), Reid W. Merryman(Harvard University), Justin Rhoades(Broad Institute), Kan Xiong(Broad Institute), Andjela Crnjac(Broad Institute), Satyen H. Gohil(Broad Institute), Catherine Song(Broad Institute), Jamie Dela Cruz(Dana-Farber Cancer Institute), Viktor A. Adalsteinsson(Broad Institute), Mikaela M. McDonough(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
|Cell|2015|4.2k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k